This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
AbbVie (ABBV) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
by Zacks Equity Research
Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.
The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance
Roche's Gazyva Gets Priority Review for Follicular Lymphoma
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
by Zacks Equity Research
Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada
by Zacks Equity Research
AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review
by Zacks Equity Research
Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.
Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data
by Arpita Dutt
Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.
Infinity (INFI) Q2 Loss Wider than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.
Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.
Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote
by Arpita Dutt
Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.
Key FDA Events to Watch Out for in Aug 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?
AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.
4 Drug Stocks in Focus this World Hepatitis Day
by Arpita Dutt
Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?
AbbVie (ABBV) Tops Q2 Earnings and Revenue
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2017 earnings surpassed estimates with revenue marginally beating the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure
Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV
by Jeffrey Hymen
The Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.
Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK
by Zacks Equity Research
Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.
Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.
Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up
by Zacks Equity Research
Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.